NYSE - Delayed Quote
USD
Bausch Health Companies Inc. (BHC)
6.56
-0.20
(-2.96%)
At close: September 4 at 4:00:02 PM EDT
6.50
-0.06
(-0.88%)
After hours: September 4 at 7:56:00 PM EDT
Trade BHC on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for BHC
- Previous Close
6.76 - Open
6.71 - Bid 6.54 x 490000
- Ask 6.56 x 570000
- Day's Range
6.53 - 6.71 - 52 Week Range
4.33 - 8.00 - Volume
1,647,934 - Avg. Volume
3,601,827 - Market Cap (intraday)
2.453B - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
-- - EPS (TTM)
-2.94 - Earnings Date (est.) Oct 28, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 10, 2010
- 1y Target Est
7.50
Recent News
View More
Performance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
BHC
6.15%
S&P/TSX Composite index (^GSPTSE)
14.58%
1-Year Return
BHC
9.02%
S&P/TSX Composite index (^GSPTSE)
26.28%
3-Year Return
BHC
22.46%
S&P/TSX Composite index (^GSPTSE)
77.72%
5-Year Return
BHC
77.63%
S&P/TSX Composite index (^GSPTSE)
75.37%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 9/2/2026
-
Market Cap
2.55B
-
Enterprise Value
21.50B
-
Trailing P/E
13.31
-
Forward P/E
1.54
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
0.24
-
Price/Book (mrq)
--
-
Enterprise Value/Revenue
1.98
-
Enterprise Value/EBITDA
10.50
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-10.12%
-
Return on Assets (ttm)
6.57%
-
Return on Equity (ttm)
--
-
Revenue (ttm)
10.85B
-
Net Income Avi to Common (ttm)
-1.1B
-
Diluted EPS (ttm)
-2.94
Balance Sheet and Cash Flow
-
Total Cash (mrq)
1.82B
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
1.43B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
6.56
-2.96%
Mkt Cap
2.453B
Industry
Drug Manufacturers—Specialty & Generic
24.50
+0.33%
Mkt Cap
12.241B
Industry
Drug Manufacturers—Specialty & Generic
17.44
-2.41%
Mkt Cap
6.074B
Industry
Drug Manufacturers—Specialty & Generic
36.36
-0.71%
Mkt Cap
42.37B
Industry
Drug Manufacturers—Specialty & Generic
18.45
-1.39%
Mkt Cap
58.92B
Industry
Drug Manufacturers—Specialty & Generic
11.97
-0.50%
Mkt Cap
9.971B
Industry
Drug Manufacturers—Specialty & Generic
34.10
+0.41%
Mkt Cap
3.8B
Industry
Drug Manufacturers—Specialty & Generic
26.35
-0.94%
Mkt Cap
1.037B
Industry
Drug Manufacturers—Specialty & Generic
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Dropping Coverage of Bausch Health Companies
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
-
Placing Both Bausch Entities Under Review Following Mixed Court Ruling on Xifaxan Patent Case
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
RatingPrice Target -
End of an Era as Papa Leaves Bausch's Board; Shares Still Trade Below FVE After 18% Gain
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
RatingPrice Target -
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
This edition features putting the Bausch & Lomb spinoff under our lens, the regulation of utility companies, wagering on Tabcorp, and International Flavors & Fragrances, BlackRock, and Fortinet.
